Pilgrim Partners Asia Pte Ltd Buys Shares of 6,800 InMode Ltd. (NASDAQ:INMD)

Pilgrim Partners Asia Pte Ltd purchased a new position in InMode Ltd. (NASDAQ:INMD) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 6,800 shares of the healthcare company’s stock, valued at approximately $114,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Quarry LP raised its position in InMode by 154.3% in the 3rd quarter. Quarry LP now owns 3,781 shares of the healthcare company’s stock worth $64,000 after buying an additional 2,294 shares during the last quarter. SBI Securities Co. Ltd. bought a new stake in InMode in the 4th quarter worth approximately $87,000. Farther Finance Advisors LLC increased its position in InMode by 26.2% during the fourth quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company’s stock valued at $93,000 after acquiring an additional 1,154 shares during the last quarter. National Bank of Canada FI lifted its stake in shares of InMode by 6.2% in the 3rd quarter. National Bank of Canada FI now owns 9,985 shares of the healthcare company’s stock worth $169,000 after purchasing an additional 579 shares during the period. Finally, WINTON GROUP Ltd bought a new position in InMode in the fourth quarter worth approximately $174,000. 68.04% of the stock is owned by institutional investors.

InMode Trading Down 3.6 %

Shares of InMode stock opened at $15.71 on Friday. InMode Ltd. has a 12 month low of $14.87 and a 12 month high of $20.01. The stock has a 50 day moving average of $18.33 and a 200 day moving average of $17.78. The firm has a market cap of $1.09 billion, a PE ratio of 6.69 and a beta of 2.08.

Analyst Ratings Changes

A number of brokerages recently commented on INMD. Needham & Company LLC reaffirmed a “hold” rating on shares of InMode in a report on Tuesday, February 4th. Barclays upped their target price on shares of InMode from $26.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, February 5th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, InMode has a consensus rating of “Hold” and an average target price of $22.25.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.